Michael Privitera is a Neurology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Effects of Diazepam on RNS Detections
Sponsor: University of Cincinnati
- Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design
Sponsor: University of Cincinnati
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202515 payments$15,175openpaymentsdata.cms.gov ↗
- SK Life Science, Inc.Program year20256 payments
- NEUROPACE, INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
98.5%Other antiepileptics30.7%Levetiracetam25%Lacosamide17%Topiramate15%Xcopri11%Epidiolex9%Topamax7%Keppra4%Levetiracetam Er4%Briviact2%Keppra Xr2%Vimpat2%Part D<11 patientsMood Stabilizer23.4%Lamotrigine46%Carbamazepine20%Lamictal13%Carbamazepine Er7%Carbatrol3%Tegretol Xr3%Tegretol3%Valproic Acid3%Lamotrigine Er2%Lamictal Xr1%Part D<11 patients+ 12 more classes in this area
Cardiovascular
0.6%Peroxisome Proliferator-activated Receptor alpha Agonist0.3%Gemfibrozil100%Part D<11 patientsBeta blocker0.3%Metoprolol Tartrate100%Part D<11 patientsSensory organs
0.5%Carbonic Anhydrase Inhibitor0.5%Acetazolamide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1989–2000 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
David Knopman, MD
Mayo Clinic Rochester
Brett Kissela, MD
Medical College of Wisconsin
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”